|
5#
楼主 |
发表于 2015-8-13 21:26:48
|
只看该作者
, X8 L/ z- {0 W) j* _Vaccines, 6th Edition
) d- ?9 h k; N" A% V+ d" j, D3 R( d1 K0 e3 ?0 Q ~' O% @
Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.1 w& b8 t% F( l# L7 F1 Q% X
* R- I% G& b- l, M9 E9 |" F7 ~
http://yun.baidu.com/share/link? ... 1&uk=3810996606+ a, s8 O/ n9 v( s: l
* j' L/ H5 L5 V" pSECTION 1: General aspects of vaccination
# b" n$ c6 i7 m& {0 L" c4 X1 A short history of vaccination 17 k0 l9 o0 j# H7 c/ w
2 Vaccine immunology 149 }( M# P) `& p
3 The vaccine industry 33
1 r0 k8 \% E7 D- U2 C4 Vaccine manufacturing 44
! T4 ?: @1 W1 P% u! K! o+ H5 Evolution of adjuvants across the centuries 58
" k( \" d% r( c6 V6 Vaccine additives and manufacturing residuals in the United States:& R1 H) U0 N* Z/ B; D' D% f
licensed vaccines 715 u6 x) E, V- h1 Z
7 Passive immunization 80. D3 O3 B% ]0 w6 A) d
8 General immunization practices 88
# a* ~, A7 c. D. fSECTION 2: Licensed vaccines
& m- E" |9 @( t7 c8 e9 J3 n h6 }9 Adenovirus vaccines 113 ]$ W$ s3 P* e% E" G
10 Anthrax vaccines 127
( p; W" K6 B& z11 Cholera vaccines 141
4 M( o# R9 G( M4 m( n! I, a+ w, H12 Diphtheria toxoid 153
/ E( `1 q8 k! e6 b8 C4 I) v13 Haemophilus influenzae vaccines 167
2 c( z' J$ P4 y, E5 [1 `% ~3 \' d14 Hepatitis A vaccines 183
3 Z; U* M! }/ p% G$ Y p15 Hepatitis B vaccines 2050 t4 w+ K" y) d/ o; J7 y: Q9 y' h
16 Human papillomavirus vaccines 235
l# _7 M8 m# A' J) V' S4 E17 Inactivated influenza vaccines 257
, j" n3 Y3 q/ w; @4 H18 Influenza vaccine-live 294
2 ~* B$ ^" z8 G% L0 [# I* [19 Japanese encephalitis vaccines 312
C. F) X6 A9 {! o; c& q2 Y+ F1 J k20 Measles vaccines 352
2 L v6 s, R; G8 p, c/ X A21 Meningococcal vaccines 388$ A* X" F! F, u* A3 L
22 Mumps vaccine 4197 q4 {$ ^, ^6 J6 j# k
23 Pertussis vaccines . 447& \" D& w$ M9 a- j" i' M/ `' d1 Q. p
24 Plague vaccines 493
$ o* T8 H" i3 A9 U25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504# R* O, y1 X9 w. X V% m
26 Pneumococcal polysaccharide vaccines 542
: Z6 m7 m8 j* B0 ]) Y27 Poliovirus vaccine-inactivated . 573
! N- n- h( _2 x28 Poliovirus vaccine-live 598
7 A% {7 F* A1 O29 Rabies vaccines .6462 [4 Y% a2 H% e
30 Rotavirus vaccines . 669
* z/ i% X i* t# S# N& q& M# Z31 Rubella vaccine 6884 D2 Q1 x( a6 A/ a! f! p' w
32 Smallpox and vaccinia 718& Q5 \* `! r' `9 p+ {2 } y- ]) u7 _
33 Tetanus toxoid 746
& `$ d" _) ?( u, f34 Tick-borne encephalitis virus vaccines 773
7 J V* a& e3 V0 B, B0 z3 p. _5 d+ R35 Tuberculosis vaccines 789$ n, U9 r/ H6 E1 ~ w) k
36 Typhoid fever vaccines 812) ~0 w# J/ X& V5 n: B, H) W6 ~
37 Varicella vaccine 837
' H+ y/ C+ F" K" z1 q5 I: |- c0 m; s38 Yellow fever vaccine 870, S$ s4 A' p; \+ m
39 Zoster vaccine 969
' ?7 b6 r3 ^& F7 z40 Combination vaccines 981
0 E- G; M& C, }- o2 T( uSECTION 3: Vaccines in development and new vaccine strategies
0 p$ ~: _9 r. f4 A S41 Biodefense and special pathogen vaccines 1008
" y2 |$ p1 Q/ Q0 L5 \2 p42 Therapeutic cancer vaccines 1018* X8 b; `* w* R* l4 H# }- V
43 Cytomegalovirus vaccines 1032
/ @/ v3 c; a1 s: \, K44 Dengue vaccines 1042 O" W& W0 R d) A# M6 L" X
45 Diarrhea caused by bacteria 1052/ i% k2 U/ U, k' ]: Q
46 Ebola vaccine 1060; j& ~2 Y' a5 o5 \; }+ J) D
47 Epstein-Barr virus vaccines 1068
' e8 ?2 C, }3 u" `- b48 Hepatitis C vaccines 1074
( O+ }' d. [& V49 Hepatitis E vaccines 1085
5 |+ R# |& _5 Y0 G9 `* `50 Herpes simplex virus vaccines 1090
. Q& _' ?* n3 C9 d51 Human immunodeficiency virus vaccines 1097& M' ^& f, b( ~+ `) ]
52 Lyme disease vaccines 11222 A; K- }" K4 Z7 s' \" W$ M3 X
53 Malaria vaccines 1133
7 M% v' s, J2 C, t1 G6 b54 Noninfectious disease vaccines 1138
; V9 ~; W6 ?1 q o4 Q8 T55 Respiratory syncytial virus and parainfluenza virus vaccines 11464 v& G1 X# [' U+ s" I
56 Parasitic disease vaccines 1154
1 o/ z: ?7 d: m8 P! H2 Z, K; I# T57 Staphylococcus aureus vaccines 1161
- W* K; ~9 g8 e/ [3 a2 e X58 Streptococcus group A vaccines 1169
% Z: g9 |8 s4 G8 K. v2 ]59 Streptococcus group B vaccines 11764 ]7 f- g" @1 R3 J' [
60 Technologies for making new vaccines 11824 C! G4 g- L: D* o; f
61 Alternative vaccine delivery methods 12008 G5 `' Q, g7 `# }! m6 @4 T
62 The development of gene-based vectors for immunization 1232, m5 V% ^6 w; r ]( _1 I' D4 ~9 @
SECTION 4: Vaccination of special groups# X6 ^5 a# U6 `/ F P# J( C$ v# \
63 Vaccination of immunocompromised hosts 1243
/ r# B3 C4 d6 S8 J) b64 Vaccination of human immunodeficiency virus-infected persons 1257) m" ?, x* _5 v, p
65 Vaccines for international travel 1270; X9 j3 L, {/ Q Q7 C# {: e
66 Vaccines for health care personnel 1290
6 K2 ]% L/ \5 D' TSECTION 5: Public health and regulatory issues
x( \* f: P+ [7 ~4 b67 Immunization in the United States 1310
, R, {# k& u' z5 {& |) X! l) d68 Immunization in Europe . 13341 v6 w( m) n! Z3 h. @. r, k
69 Immunization in the Asia-Pacific region 1353
+ K6 N0 ^( E( |) U70 Immunization in developing countries 13695 b/ J+ R/ x% n6 X2 ^( C y
71 Community immunity 1395
. P! P& F8 o% X8 J3 X B1 B72 Economic analyses of vaccine policies 1413# a8 j j" w5 m; z
73 Regulation and testing of vaccines 1427
# v0 |% X9 e8 L( {; z- U74 Regulation of vaccines in Europe 1447
9 f Q. ?8 z( N) l& C8 @75 Regulation of vaccines in developing countries 1454% ?! A3 P8 O1 N+ A! c' X
76 Vaccine safety 1464( Z8 [7 ^ v, c5 I$ x
77 Legal issues . 14818 _8 w% V2 @# R/ X7 V
78 Ethics 1508; k b, D$ @& D+ L, r6 G5 I% q
2 V" X: o/ V) K3 }$ n
8 U9 ~. N; q$ q0 L9 l% t G9 L. H1 G |
|